Genelux Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNLX research report →
Range $16 – $20
Price Chart
About the company
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers.
- CEO
- Thomas D. Zindrick
- IPO
- 2023
- Employees
- 26
- HQ
- Westlake Village, CA, US
Get TickerSpark's AI analysis on GNLX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $113.89M
- P/E
- -2.85
- Fwd P/E
- 2.84
- PEG
- 1.20
- P/S
- 14236.83
- P/B
- 7.09
- EV/EBITDA
- -3.13
- Div Yield
- 0.00%
- Gross Margin
- -1762.50%
- Op Margin
- -445200.00%
- Net Margin
- -422412.50%
- ROE
- -195.42%
- ROIC
- -192.18%
Latest fiscal year · YoY change
- Revenue
- $8.00K+0.0%
- Gross Profit
- $-566,000+36.8%
- Op Income
- $-33,214,000
- Net Income
- $-32,145,000-7.6%
- EPS
- $-0.86+9.5%
- OCF Growth
- -19.0%
- FCF Growth
- -22.0%
- 52W High
- $8.54
- 52W Low
- $2.29
- 50D MA
- $2.64
- 200D MA
- $2.83
- Beta
- 0.58
- RSI (14)
- 49
- Avg Volume
- 271.28K
No earnings-call transcripts are available for GNLX yet.
- Free Float
- 80.6%
- Shares Outstanding
- 44.84M
- Float Shares
- 36.13M
of shares held by institutions
71 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Woodward Diversified Capital, LLC | 2.26M | ▲ 144.93K |
| Vanguard Capital Management LLC | 1.68M | ▼ 17.76K |
| Vanguard Group Inc | 1.55M | ▲ 132.07K |
| Bleichroeder LP | 1.38M | 0 |
| Blackrock, Inc. | 439.60K | ▲ 33.73K |
| Geode Capital Management, LLC | 439.21K | ▼ 14.55K |
| Cm Management, LLC | 400.00K | ▲ 150.00K |
| Bank Of America Corp | 328.80K | ▲ 4.94K |
| Vanguard Fiduciary Trust Co | 236.34K | ▼ 15.27K |
| Flputnam Investment Management Co | 231.41K | ▼ 49.50K |
| Global Retirement Partners, LLC | 227.85K | ▲ 227.85K |
| Lpl Financial LLC | 157.86K | ▲ 18.82K |
Held by 22 ETFs
Biggest fund positions in GNLX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 31, 26 | Cappello Joseph | sell | 10,257 |
| Aug 31, 26 | Zindrick Thomas | sell | 34,463 |
| Aug 31, 26 | Yu Yong | sell | 9,683 |
| Aug 4, 26 | Yu Yong | sell | 653 |
| Aug 4, 26 | Cappello Joseph | sell | 653 |
| Aug 4, 26 | Zindrick Thomas | sell | 3,023 |
| Jul 1, 26 | Smither John W | sell | 12,000 |
| Jun 16, 26 | Pulisic Matthew | other | 278,906 |
| Jun 16, 26 | Groen Eric | other | 233,957 |
| Jun 16, 26 | Cappello Joseph | other | 174,841 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GNLX coverage
Recent articles, reports, and earnings notes.
No research on GNLX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GNLX report →Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
globenewswire.com · Sep 9
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
globenewswire.com · Aug 13
Genelux (GNLX) Projected to Post Quarterly Earnings on Thursday
defenseworld.net · Aug 5
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
globenewswire.com · Jun 30
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
globenewswire.com · May 7
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
globenewswire.com · Mar 19
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
globenewswire.com · Jan 12
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
globenewswire.com · Jan 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.